Author: Lunai Bioworks (Nasdaq: LNAI)

Parkinson’s Disease Platform Advanced via Exclusive Global Agreement with Tanaist, Inc. Adding Human Cellular Phenotyping for Lunai Bioworks (Nasdaq: LNAI)

September 24, 2026
$400M to $1.2 Billion US Countermeasures Program Presents Huge Opportunity for New AI Platform to Meet Emerging Battlefield and Terrorism Threats: Lunai Bioworks (Nasdaq: LNAI)

March 23, 2026

Parkinson’s Disease Platform Advanced via Exclusive Global Agreement with Tanaist, Inc. Adding Human Cellular Phenotyping for Lunai Bioworks (Nasdaq: LNAI)